Prior to randomization, patients in the study were stratified according to first-line cancer therapy, type of EGFR-targeted agent prescribed or anticipated (TKI versus mAb), and the use of any concurrent medication that might be associated with increased sensitivity to sun exposure.40 Overall, 110 rash-free patients (39 lung, 45 CRC and 26 other malignancy) were randomized to receive an application of SPF60 sunscreen twice daily for 4 weeks versus placebo. The gene discussed is EGFR; the disease is cancer.